Skadden, Arps, Slate, Meagher & Flom and Jones Day, together with Wilmer Cutler Pickering Hale and Dorr, are advising on Japanese pharmaceutical research company Astellas Pharma’s $5.9 billion acquisition of U.S. drugmaker Iveric Bio.

Jones Day is acting as legal counsel to Tokyo-listed Astellas in its multi-billion-dollar takeover of Iveric Bio, which is being represented by Skadden and Wilmer Cutler, according to a statement announcing the deal.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]